Are Psychedelics the Fountain of Youth?

dr Andrew Steele, a physics professor who has ventured into the field of biology, presents a fascinating perspective on longevity in his new book. He emphasizes that aging, not cancer or heart disease, is the root cause of the most significant suffering and deaths worldwide. dr Steele suggests that by finding pharmacological cures that target the cells responsible for deteriorating tissue function, we could unlock the potential for humans to live up to 200 years.

A group of researchers from Harvard Medical School has made a groundbreaking discovery that sheds new light on aging. In an unprecedented international study, the team discovered that changes in the organization and regulation of DNA, known as epigenetics, can trigger aging in an organism independent of changes in the genetic code. Their research found that disruption of epigenetic information leads to aging in mice, and when the integrity of the epigenome is restored, the signs of aging are reversed.

According to David Sinclair, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research, the recent discovery reinforces the idea that mammalian cells have a backup copy of the epigenetic software. By accessing this backup, it may be possible to rejuvenate aging cells, restoring them to a more youthful and healthy state.

As reported in the Genetics Literacy Project, the search for molecules that can reverse the aging process is expected to attract tens of billions of dollars in research funding. Sinclair, who also heads Life Biosciences, a biotech company focused on developing therapeutics to prevent, treat and potentially reverse age-related diseases, is leading this human lifespan extension effort.

Psychedelics are becoming a major substance in focus

The Longevity Science Foundation (LSF) made an exciting announcement at the Wonderland 2022 conference in November. The non-profit organization dedicated to funding research to advance longer and healthier human lifespans unveiled a new funding initiative for psychedelics research. This new project is a collaboration between the LSF and PsyMed Ventures, a company focused on investing in the psychedelics sector.

The Longevity Science Foundation (LSF) reports that the use of psychedelics to treat mental illness is gaining momentum at an unprecedented rate. Compounds like MDMA, ketamine, and psilocybin have shown encouraging results in treating PTSD, depression, and addiction. Additionally, researchers have shown that ketamine and psilocybin can help regenerate neural connections, which LSF says could have wide-reaching implications for the development of treatments for neurodegenerative diseases associated with aging.

The LSF has committed $1 billion in research grants, institutional support, and project funding over the next decade to support its mission of promoting healthy human longevity. Through this initiative, the foundation aims to support psychedelics companies engaged in research aimed at managing, delaying or even reversing age-related mental and brain disorders that investigate mechanisms underlying the effects of psychedelic compounds , or other groundbreaking studies relevant to both longevity and psychedelics.

The Healthy Longevity Medicine Society (HLMS), an LSF partner, aims to create, coordinate and promote a comprehensive clinical research program covering all facets of longevity medicine. The Company intends to initiate various programs such as the standardization of diagnostics and the creation of a clinical trials network.

Researchers have discovered drugs that can extend the lifespan of animals, and one of SPF’s partners, rapamycin, has shown the ability to prevent aging in mice. According to LSF, the drug has been found to reduce cognitive decline and delay the onset of Alzheimer’s disease.

Scientists have discovered that a drug to fight leukemia combined with a natural chemical compound derived from plants has the potential to prolong human life. In addition, metformin, a drug that has been prescribed for diabetes for decades, also shows promise in the field of life extension research.

Psychedelic therapy is finally being recognized as a legitimate treatment option.

LSF executive coordinator Garri Zmudze emphasizes the importance of mental health for longevity, stating that a healthy mind is just as important as a healthy body. LSF funding of psychedelic research contributes to a growing body of knowledge transforming brain health and longevity.

Psychedelics researchers are exploring the potential role of psychedelics in prolonging life by examining their effects on neurons. The brain’s ability to change throughout life, known as neuroplasticity, is believed to be a critical component of life extension. Neuroplasticity includes changes in cell structure, structural plasticity, and changes in the efficiency of synaptic transmission, also known as functional plasticity.

Psychedelics’ ability to repair atrophied neurons, which occurs in depressed patients, results in improved synaptic connectivity, or cell-to-cell communication. Experimental studies of LSD, ayahuasca, and psilocybin in placebo-controlled settings have shown positive results in reducing symptoms of depression, anxiety, and addiction after just one or two doses, with measurable effects lasting anywhere from three weeks to six months. Researchers believe that the persistence of psychological effects beyond the substance’s presence in the blood indicates a biological adaptation.

Researchers have suggested that psychedelics may have anti-aging effects, albeit more related to personality changes. With up to 20% of the world’s population expected to be over 60 by 2050, studying aging is an important scientific task. However, the ultimate goal remains unclear: will the research lead to therapies to prevent disease or directly aim at extending lifespan?

Sinclair predicted that human aging reversal could occur as early as 2025. Psychedelic companies are reportedly showing interest in the work of Sinclair, who secured a remarkable $158 million in funding for Life Biosciences.

Diploma

The field of psychedelics has long been devoted to discovering new therapies for medical problems that have yet to be addressed. Eleusis, an industry company focused on the effects of aging, has discovered that LSD can help treat the cognitive decline associated with Alzheimer’s disease.

Her research shows that aging is associated with decreased neuroplasticity and that age is a key risk factor for dementia. “The decline in neuroplasticity that accompanies aging could play an important role in the loss of synapses and neurons in Alzheimer’s disease,” explains Eleusis.

PSYCHEDELICS FOR HEALTH, READ MORE…

PSYCHEDELICS FOR MENTAL HEALTH WHICH WORK NOW!